Recent Finacing
Recent Raise
AgeneBio develops therapeutics to slow amnestic mild cognitive impairment and early Alzheimer’s by targeting hippocampal overactivity, repurposing levetiracetam and advancing a GABA-A α5 PAM through clinical development.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at AgeneBio.
